Copyright
©The Author(s) 2018.
World J Transplantation. Oct 22, 2018; 8(6): 203-219
Published online Oct 22, 2018. doi: 10.5500/wjt.v8.i6.203
Published online Oct 22, 2018. doi: 10.5500/wjt.v8.i6.203
Figure 4 Response of complement 3 glomerulopathy subtypes to eculizumab therapy based on laboratory parameters and tissue (histopathological) response.
A: Dense deposit disease response to eculizumab therapy[66]; B: Complement 3 glomerulonephritis response to eculizumab therapy[66]. CFH: Complement factor H; CFI: Complement factor I; C3Nef: C3 nephritic factor.
- Citation: Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, Halawa A. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World J Transplantation 2018; 8(6): 203-219
- URL: https://www.wjgnet.com/2220-3230/full/v8/i6/203.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i6.203